一名免疫功能正常的患者在接受泌尿外科Rezum手术后发生耐碳青霉烯类无丙二酸柠檬酸杆菌和耐万古霉素肠球菌菌血症。
Carbapenem-resistant Citrobacter amalonaticus and VRE bacteraemia in an immunocompetent patient after a urological Rezum procedure.
作者信息
Midlick David, Harhay Jason, Summers Nathan A
机构信息
College of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Department of Medicine, Division of Infectious Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
出版信息
Access Microbiol. 2024 Oct 10;6(10). doi: 10.1099/acmi.0.000852.v4. eCollection 2024.
Abstract
In this report, we discuss the case of a 62-year-old man who presented with gross haematuria, fever, and chills 1 day after undergoing a Rezum procedure and was found to have carbapenem-resistant and vancomycin-resistant bacteraemia. The patient was treated with daptomycin, eravacycline, and ceftalozane-tazobactam with positive results. We discuss our case and treatment of bacteraemia, a pathogen with limited existing literature on its incidence, presentation, and treatment.
摘要
在本报告中，我们讨论了一名62岁男性的病例，该患者在接受Rezum手术后1天出现肉眼血尿、发热和寒战，被发现患有耐碳青霉烯类和耐万古霉素菌血症。患者接受了达托霉素、依拉环素和头孢洛扎-他唑巴坦治疗，结果良好。我们讨论了我们对这种菌血症的病例及治疗情况，对于这种病原体，关于其发病率、临床表现和治疗的现有文献有限。
相似文献
1
Carbapenem-resistant Citrobacter amalonaticus and VRE bacteraemia in an immunocompetent patient after a urological Rezum procedure.一名免疫功能正常的患者在接受泌尿外科Rezum手术后发生耐碳青霉烯类无丙二酸柠檬酸杆菌和耐万古霉素肠球菌菌血症。
Access Microbiol. 2024 Oct 10;6(10). doi: 10.1099/acmi.0.000852.v4. eCollection 2024.
2
Characterization of a carbapenem-resistant coharbouring and genes.耐碳青霉烯肠杆菌同时携带 和 基因的特性研究。
J Med Microbiol. 2021 Jun;70(6). doi: 10.1099/jmm.0.001364.
3
Risk factors and outcomes associated with vancomycin-resistant Enterococcus faecium and ampicillin-resistant Enterococcus faecalis bacteraemia: A 10-year study in a tertiary-care centre in Mexico City.耐万古霉素粪肠球菌和耐氨苄西林粪肠球菌菌血症的相关危险因素和结局：墨西哥城一家三级医疗中心的 10 年研究。
J Glob Antimicrob Resist. 2021 Mar;24:198-204. doi: 10.1016/j.jgar.2020.12.005. Epub 2020 Dec 24.
4
Vancomycin-resistant enterococcus bacteraemia in an endemic region: clinical features and genomic analysis: a 12-year cohort.万古霉素耐药肠球菌菌血症在流行地区的临床特征和基因组分析：一项 12 年的队列研究。
J Hosp Infect. 2022 Mar;121:105-113. doi: 10.1016/j.jhin.2021.11.021. Epub 2021 Dec 9.
5
Development of systemic bacteraemia after oral inoculation of vancomycin-resistant enterococci in mice.小鼠经口接种耐万古霉素肠球菌后全身性菌血症的发生情况。
J Med Microbiol. 2001 Aug;50(8):695-701. doi: 10.1099/0022-1317-50-8-695.
6
Emergence of plasmid-mediated colistin resistance -3.5 gene in and isolated from healthy individual in Thailand.泰国健康个体中分离出的 和 携带的质粒介导的黏菌素耐药基因 -3.5 的出现。
Front Cell Infect Microbiol. 2023 Jan 4;12:1067572. doi: 10.3389/fcimb.2022.1067572. eCollection 2022.
7
Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?耐万古霉素肠球菌菌血症：达托霉素与利奈唑胺的疗效相同吗？
J Antimicrob Chemother. 2009 Jul;64(1):175-80. doi: 10.1093/jac/dkp154. Epub 2009 May 7.
8
Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose.达托霉素与利奈唑胺治疗万古霉素耐药肠球菌菌血症：达托霉素剂量的影响。
Clin Microbiol Infect. 2016 Oct;22(10):890.e1-890.e7. doi: 10.1016/j.cmi.2016.07.018. Epub 2016 Jul 27.
9
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
10
Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?万古霉素耐药肠球菌菌血症与达托霉素：是否需要更高剂量？
J Antimicrob Chemother. 2011 Sep;66(9):2112-8. doi: 10.1093/jac/dkr255. Epub 2011 Jun 22.
本文引用的文献
1
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
2
Ceftolozane-tazobactam: When, how and why using it?头孢洛扎他唑巴坦：何时、如何以及为何使用？
Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):35-37. doi: 10.37201/req/s01.10.2021. Epub 2021 Sep 30.
3
A Real-World Assessment of Clinical Outcomes and Safety of Eravacycline: A Novel Fluorocycline.依拉环素的临床结局与安全性的真实世界评估：一种新型氟环素
Infect Dis Ther. 2020 Dec;9(4):1017-1028. doi: 10.1007/s40121-020-00351-0. Epub 2020 Oct 15.
4
Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy.替加环素单药成功治疗耐多药引起的急性前列腺炎
Open Forum Infect Dis. 2020 Jan 9;7(1):ofz551. doi: 10.1093/ofid/ofz551. eCollection 2020 Jan.
5
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.碳青霉烯类耐药革兰氏阴性菌感染的治疗选择。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. doi: 10.1093/cid/ciz830.
6
Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia.Rezum：一种用于良性前列腺增生的新型经尿道水蒸气疗法。
Ther Adv Urol. 2018 Aug 12;10(11):327-333. doi: 10.1177/1756287218793084. eCollection 2018 Nov.
7
Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.达托霉素剂量对万古霉素耐药、达托霉素敏感粪肠球菌菌血症结局的影响。
Clin Infect Dis. 2017 Apr 15;64(8):1026-1034. doi: 10.1093/cid/cix024.
8
Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.比较标准剂量、中剂量和高剂量达托霉素治疗退伍军人事务部患者耐万古霉素肠球菌菌血症的疗效和安全性。
Clin Infect Dis. 2017 Mar 1;64(5):605-613. doi: 10.1093/cid/ciw815.
9
Citrobacter amalonaticus human urinary tract infections, Marseille, France.无丙二酸柠檬酸杆菌致人类尿路感染，法国马赛
New Microbes New Infect. 2016 Jan 21;11:1-5. doi: 10.1016/j.nmni.2016.01.003. eCollection 2016 May.
10
Efficacy and Safety of Rezūm System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.Rezum系统水蒸气治疗良性前列腺增生继发下尿路症状的疗效与安全性
Urology. 2015 Nov;86(5):1042-7. doi: 10.1016/j.urology.2015.05.046. Epub 2015 Jul 26.
Zotero 插件